SCHEMBL6448931

SCHEMBL6448931

COC(=O)c1ccc(C(=O)Nc2nnc(-c3cc(Cl)cc(Cl)c3O)s2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 3/20 0.46
NPC1 O15118 5/20 0.46
RAB9A P51151 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
RXFP1 Q9HBX9 2/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
HPGD P15428 3/20 0.46
ALDH1A1 P00352 3/20 0.46
TP53 P04637 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 2/20 0.46
PKM P14618 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
CSNK2A2 P19784 1/20 0.45
CSNK2A1 P68400 1/20 0.45
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6448237 0.92 STK39 (0.49) PTGER3NPC1RAB9AMEN1KMT2A
SCHEMBL6447207 0.90 WNT3A (0.46) PTGER3NPC1RAB9AMEN1KMT2A
SCHEMBL6446020 0.90 KMT2A (0.48) PTGER3NPC1RAB9AMEN1KMT2A
SCHEMBL6445400 0.89 MAPK1 (0.45) PTGER3NPC1RAB9AMEN1KMT2A
SCHEMBL6324529 0.89 MAPT (0.52) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL6445732 0.88 TSHR (0.48) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL6447140 0.87 PTGER3 (0.45) PTGER3NPC1RAB9AMEN1KMT2A
SCHEMBL6451555 0.87 CSNK2A2 (0.55) PTGER3NPC1RAB9AMEN1KMT2A
SCHEMBL6445474 0.87 KDM4E (0.53) PTGER3RAB9AMEN1KMT2ARXFP1
SCHEMBL6445925 0.86 MAPT (0.53) PTGER3NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US claimed
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 PTGER3 332/4885NPC1 1404/4885RAB9A 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.